S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:ACOR - Acorda Therapeutics Stock Price, Forecast & News

$1.76
+0.07 (+4.14 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$1.63
Now: $1.76
$1.77
50-Day Range
$1.52
MA: $1.91
$2.62
52-Week Range
$1.49
Now: $1.76
$17.57
Volume952,513 shs
Average Volume1.25 million shs
Market Capitalization$84.53 million
P/E Ratio0.97
Dividend YieldN/A
Beta1.15
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$471.43 million
Cash Flow$2.41 per share
Book Value$12.87 per share

Profitability

Net Income$33.68 million
Net Margins-155.89%

Miscellaneous

Employees474
Market Cap$84.53 million
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.


Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) posted its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.05. The biopharmaceutical company had revenue of $47.72 million for the quarter, compared to analyst estimates of $43.23 million. Acorda Therapeutics had a negative return on equity of 12.96% and a negative net margin of 155.89%. The business's revenue was down 66.6% compared to the same quarter last year. During the same period last year, the company earned $0.17 earnings per share. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

9 equities research analysts have issued 1-year price objectives for Acorda Therapeutics' shares. Their forecasts range from $1.40 to $30.00. On average, they anticipate Acorda Therapeutics' stock price to reach $11.43 in the next year. This suggests a possible upside of 549.1% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.

What is the consensus analysts' recommendation for Acorda Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 3 sell ratings, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019)
  • 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)

Has Acorda Therapeutics been receiving favorable news coverage?

Press coverage about ACOR stock has been trending positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View News Stories for Acorda Therapeutics.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 11,750,000 shares, an increase of 9.6% from the November 14th total of 10,720,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is presently 7.0 days. Currently, 24.9% of the shares of the company are short sold. View Acorda Therapeutics' Current Options Chain.

Who are some of Acorda Therapeutics' key competitors?

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Celgene (CELG), Applied Materials (AMAT), Gilead Sciences (GILD), salesforce.com (CRM), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Biogen (BIIB) and Clovis Oncology (CLVS).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
  • Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (5.78%), State Street Corp (2.94%), Point72 Asset Management L.P. (2.10%), Russell Investments Group Ltd. (0.92%), Diamond Hill Capital Management Inc. (0.76%) and Massachusetts Financial Services Co. MA (0.53%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which institutional investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., Scopia Capital Management LP, Diamond Hill Capital Management Inc., Barclays PLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Acorda Therapeutics company stock in the last year include Jane Wasman, Lauren M Sabella, Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

Which institutional investors are buying Acorda Therapeutics stock?

ACOR stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Strs Ohio, Public Employees Retirement System of Ohio, Dupont Capital Management Corp, Millennium Management LLC, Virginia Retirement Systems ET AL, SG Americas Securities LLC and Voya Investment Management LLC. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $1.76.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $84.53 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.View Additional Information About Acorda Therapeutics.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is http://www.acorda.com/.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  522 (Vote Underperform)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel